Therefore, albGM-CSF, delivered via either the intravenous or subcutaneous route, offers superior therapeutic efficacy against chronic TB relative to GM-CSF or no treatment (Fig. 4a, b). The gene discussed is CSF2; the disease is tuberculosis.